<DOC>
	<DOCNO>NCT00112229</DOCNO>
	<brief_summary>The purpose study determine whether vaccination tumor antigenic peptide CpG Montanide adjuvants induce immune response melanoma patient assess safety vaccination .</brief_summary>
	<brief_title>Immunotherapy HLA-A2 Positive Stage III/IV Melanoma Patients</brief_title>
	<detailed_description>Immune therapy tumor antigenic peptide generally quite well tolerate . However , immune activation often weak even undetectable , clinical response ( supposedly correspond protective immunity ) unfortunately infrequent . Further progress require improve vaccine , goal increase strength immune activation . The tumor antigenic peptide Melan-A/Mart-1 ( EAA ELA ) Tyrosinase ( YMD ) combine two drug study , know enhance immune response : first , CpG 7909 oligodeoxynucleotides , second , Montanide ISA-51 . - Group 1 : vaccination Melan-A analog peptide + CpG Montanide adjuvant ; - Group 2 : vaccination Melan-A natural peptide + CpG Montanide adjuvant ; - Group 3 : vaccination Melan-A natural Tyrosinase peptide + CpG Montanide adjuvant ; - Group 4 : vaccination Melan-A analog Tyrosinase peptides + CpG Montanide adjuvant .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm stage III stage IV melanoma Tumor expression MelanA +/ Tyrosinase Human leukocyte antigenA2 ( HLAA2 ) positive Clinically significant heart disease Serious illnesses , eg , serious infection require antibiotic , bleed disorder uncontrolled peptic ulcer , seizure central nervous system disorder History immunodeficiency disease autoimmune disease Coagulation bleeding disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Melan-A/Mart-1 peptide</keyword>
	<keyword>Tyrosinase peptide</keyword>
	<keyword>CpG</keyword>
	<keyword>Montanide</keyword>
</DOC>